XML 26 R17.htm IDEA: XBRL DOCUMENT
v3.25.3

SEGMENT AND GEOGRAPHIC DATA | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
SEGMENT AND GEOGRAPHIC DATA | NOTE 10— SEGMENT AND GEOGRAPHIC DATA Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing performance of operating segments, has been identified as the Chief Executive Officer (the “CODM”). The Company conducts its business through two reportable segments: Dental and Medical. These segments offer different products and services to various customer base. The CODM assesses the financial performance of the segment and decides how to allocate resources based on Product sales, net, and operating income (loss). Certain reclassifications have been made to the 2025 unaudited condensed consolidated financial statements to conform to the 2024 unaudited condensed consolidated financial statement presentation. These reclassifications had no effect on net loss or cash flows as previously reported. The Company provides general corporate services to its segments; however, these services are not considered when making operating decisions and assessing segment performance. These services are reported under “Corporate Services” below and these include costs associated with executive management, investor relations, patents, trademarks, licensing agreements, new instruments developments, financing activities and public company compliance. The following tables present information about our reportable and operating segments for the three and nine months ended September 30, 2025, and 2024: SCHEDULE OF REPORTABLE AND OPERATING SEGMENTS
|  | Corporate |  |  | Dental |  |  | Medical |  |  | Grand Total |
|  | Three Months ending September 30, 2025 |
|  | Corporate |  |  | Dental |  |  | Medical |  |  | Grand Total |
Product sales, net |  | $ | - |  |  | $ | 2,318,993 |  |  | $ | 41,124 |  |  | $ | 2,360,117 |
Cost of products sold |  |  | - |  |  |  | 718,481 |  |  |  | 766 |  |  |  | 719,247 |
Gross Margin |  |  | - |  |  |  | 1,600,512 |  |  |  | 40,358 |  |  |  | 1,640,870 |
Salaries & employee benefits |  |  | 387,591 |  |  |  | 440,807 |  |  |  | 170,429 |  |  |  | 998,827 |
Stock compensation |  |  | 363,084 |  |  |  | - |  |  |  | - |  |  |  | 363,084 |
Royalties |  |  | - |  |  |  | 116,540 |  |  |  | 2,065 |  |  |  | 118,605 |
Marketing |  |  | 21,321 |  |  |  | 32,980 |  |  |  | 9,249 |  |  |  | 63,550 |
Rent & occupancy costs |  |  | 22,805 |  |  |  | 12,521 |  |  |  | 7,826 |  |  |  | 43,152 |
Consultants and professional services fees |  |  | 550,229 |  |  |  | 37,633 |  |  |  | 65,633 |  |  |  | 653,495 |
Insurance |  |  | 40,907 |  |  |  | 45,051 |  |  |  | 39,969 |  |  |  | 125,927 |
Warehousing expense |  |  | 2,885 |  |  |  | 107,564 |  |  |  | 7,465 |  |  |  | 117,914 |
Regulatory expense |  |  | 42,446 |  |  |  | 18,192 |  |  |  | 3,862 |  |  |  | 64,500 |
Travel expense |  |  | 23,364 |  |  |  | 4,518 |  |  |  | 9,178 |  |  |  | 37,060 |
Research and development expense |  |  | - |  |  |  | 15,401 |  |  |  | 825 |  |  |  | 16,226 |
Depreciation and amortization |  |  | 20,104 |  |  |  | - |  |  |  | - |  |  |  | 20,104 |
Other Segments items |  |  | 76,116 |  |  |  | 75,913 |  |  |  | 868 |  |  |  | 152,897 |
Total operating expenses |  |  | 1,550,852 |  |  |  | 907,120 |  |  |  | 317,369 |  |  |  | 2,775,341 |
Operating income (loss) |  | $ | (1,550,852 | ) |  | $ | 693,392 |  |  | $ | (277,011 | ) |  | $ | (1,134,471 | )
|  | Corporate |  |  | Dental |  |  | Medical |  |  | Grand Total |
|  | Three Months ending September 30, 2024 |
|  | Corporate |  |  | Dental |  |  | Medical |  |  | Grand Total |
Product sales, net |  | $ | - |  |  | $ | 2,468,205 |  |  | $ | 45,600 |  |  | $ | 2,513,805 |
Cost of products sold |  |  | - |  |  |  | 674,164 |  |  |  | 3,421 |  |  |  | 677,585 |
Gross Margin |  |  | - |  |  |  | 1,794,041 |  |  |  | 42,179 |  |  |  | 1,836,220 |
Salaries & employee benefits |  |  | 427,416 |  |  |  | 396,533 |  |  |  | 200,992 |  |  |  | 1,024,941 |
Stock compensation |  |  | 484,077 |  |  |  | - |  |  |  | - |  |  |  | 484,077 |
Royalties |  |  | - |  |  |  | 124,178 |  |  |  | 2,370 |  |  |  | 126,548 |
Marketing |  |  | 20,348 |  |  |  | 80,316 |  |  |  | 13,943 |  |  |  | 114,607 |
Rent & occupancy costs |  |  | 15,501 |  |  |  | 12,243 |  |  |  | 7,652 |  |  |  | 35,396 |
Consultants and professional services fees |  |  | 520,204 |  |  |  | 42,850 |  |  |  | 107,170 |  |  |  | 670,224 |
Insurance |  |  | 140,021 |  |  |  | - |  |  |  | - |  |  |  | 140,021 |
Warehousing expense |  |  | 3,615 |  |  |  | 106,723 |  |  |  | 7,459 |  |  |  | 117,797 |
Regulatory expense |  |  | 91,881 |  |  |  | 10,977 |  |  |  | 7,964 |  |  |  | 110,822 |
Travel expense |  |  | 11,425 |  |  |  | 17,492 |  |  |  | 25,141 |  |  |  | 54,058 |
Research and development expense |  |  |  |  |  |  | 232,056 |  |  |  | - |  |  |  | 232,056 |
Depreciation and amortization |  |  | 8,574 |  |  |  |  |  |  |  |  |  |  |  | 8,574 |
Other Segments items |  |  | 91,425 |  |  |  | 92,355 |  |  |  | 2,498 |  |  |  | 186,278 |
Total operating expenses |  |  | 1,814,487 |  |  |  | 1,115,723 |  |  |  | 375,189 |  |  |  | 3,305,399 |
Operating income (loss) |  | $ | (1,814,487 | ) |  | $ | 678,318 |  |  | $ | (333,010 | ) |  | $ | (1,469,179 | )
|  | Corporate |  |  | Dental |  |  | Medical |  |  | Grand Total |
|  | Nine Months ending September 30, 2025 |
|  | Corporate |  |  | Dental |  |  | Medical |  |  | Grand Total |
Product sales, net |  | $ | - |  |  | $ | 6,791,353 |  |  | $ | 124,650 |  |  | $ | 6,916,003 |
Cost of products sold |  |  | - |  |  |  | 2,008,242 |  |  |  | 1,850 |  |  |  | 2,010,092 |
Gross Margin |  |  | - |  |  |  | 4,783,111 |  |  |  | 122,800 |  |  |  | 4,905,911 |
Salaries & employee benefits |  |  | 711,476 |  |  |  | 1,322,768 |  |  |  | 569,276 |  |  |  | 2,603,520 |
Stock compensation |  |  | 853,550 |  |  |  | - |  |  |  | - |  |  |  | 853,550 |
Royalties |  |  | - |  |  |  | 344,642 |  |  |  | 6,233 |  |  |  | 350,875 |
Marketing |  |  | 35,738 |  |  |  | 164,656 |  |  |  | 53,476 |  |  |  | 253,870 |
Rent & occupancy costs |  |  | 57,216 |  |  |  | 38,894 |  |  |  | 24,309 |  |  |  | 120,419 |
Consultants and professional services fees |  |  | 2,333,311 |  |  |  | 178,428 |  |  |  | 326,992 |  |  |  | 2,838,731 |
Insurance |  |  | 124,282 |  |  |  | 139,273 |  |  |  | 122,483 |  |  |  | 386,038 |
Warehousing expense |  |  | 9,123 |  |  |  | 326,564 |  |  |  | 33,426 |  |  |  | 369,113 |
Regulatory expense |  |  | 371,267 |  |  |  | 101,186 |  |  |  | 9,261 |  |  |  | 481,714 |
Travel expense |  |  | 39,843 |  |  |  | 62,056 |  |  |  | 74,470 |  |  |  | 176,369 |
Research and development expense |  |  | - |  |  |  | 427,297 |  |  |  | 9,838 |  |  |  | 437,135 |
Depreciation and amortization |  |  | 59,040 |  |  |  | - |  |  |  | - |  |  |  | 59,040 |
Other Segments items |  |  | 229,071 |  |  |  | 349,148 |  |  |  | 14,273 |  |  |  | 592,492 |
Total operating expenses |  |  | 4,823,917 |  |  |  | 3,454,912 |  |  |  | 1,244,037 |  |  |  | 9,522,866 |
Operating income (loss) |  | $ | (4,823,917 | ) |  | $ | 1,328,199 |  |  | $ | (1,121,237 | ) |  | $ | (4,616,955 | )
|  | Corporate |  |  | Dental |  |  | Medical |  |  | Grand Total |
|  | Nine Months ending September 30, 2024 |
|  | Corporate |  |  | Dental |  |  | Medical |  |  | Grand Total |
Product sales, net |  | $ | - |  |  | $ | 6,544,394 |  |  | $ | 72,020 |  |  | $ | 6,616,414 |
Cost of products sold |  |  | - |  |  |  | 1,685,119 |  |  |  | 7,769 |  |  |  | 1,692,888 |
Gross Margin |  |  | - |  |  |  | 4,859,275 |  |  |  | 64,251 |  |  |  | 4,923,526 |
Salaries & employee benefits |  |  | 985,315 |  |  |  | 1,150,945 |  |  |  | 599,802 |  |  |  | 2,736,062 |
Stock compensation |  |  | 1,003,192 |  |  |  | - |  |  |  | 2,078 |  |  |  | 1,005,270 |
Royalties |  |  | - |  |  |  | 333,499 |  |  |  | 3,691 |  |  |  | 337,190 |
Marketing |  |  | 68,694 |  |  |  | 297,753 |  |  |  | 31,660 |  |  |  | 398,107 |
Rent & occupancy costs |  |  | 51,300 |  |  |  | 36,729 |  |  |  | 22,956 |  |  |  | 110,985 |
Consultants and professional services fees |  |  | 1,642,583 |  |  |  | 126,902 |  |  |  | 593,932 |  |  |  | 2,363,417 |
Insurance |  |  | 343,903 |  |  |  | 44,913 |  |  |  | 33,598 |  |  |  | 422,414 |
Warehousing expense |  |  | 9,769 |  |  |  | 333,426 |  |  |  | 27,331 |  |  |  | 370,526 |
Regulatory expense |  |  | 329,698 |  |  |  | 16,040 |  |  |  | 14,296 |  |  |  | 360,034 |
Travel expense |  |  | 39,051 |  |  |  | 66,706 |  |  |  | 72,295 |  |  |  | 178,052 |
Research and development expense |  |  | - |  |  |  | 638,226 |  |  |  | 3,009 |  |  |  | 641,235 |
Depreciation and amortization |  |  | 28,735 |  |  |  | - |  |  |  | - |  |  |  | 28,735 |
Other Segments items |  |  | 388,639 |  |  |  | 288,116 |  |  |  | 9,414 |  |  |  | 686,169 |
Total operating expenses |  |  | 4,890,879 |  |  |  | 3,333,255 |  |  |  | 1,414,062 |  |  |  | 9,638,196 |
Operating income (loss) |  | $ | (4,890,879 | ) |  | $ | 1,526,020 |  |  | $ | (1,349,811 | ) |  | $ | (4,714,670 | )
|  | September 30, 2025 |
|  | Dental |  |  | Medical |  |  | Corporate |  |  | Total |
Total Assets |  | $ | 6,504,045 |  |  | $ | 376,246 |  |  | $ | 1,605,732 |  |  | $ | 8,486,023 |
|  |  | 6,504,045 |  |  |  | 376,246 |  |  |  | 1,605,732 |  |  |  | 8,486,023 |
|  | December 31, 2024 |
|  | Dental |  |  | Medical |  |  | Corporate |  |  | Total |
Total Assets |  | $ | 5,359,734 |  |  | $ | 444,513 |  |  | $ | 3,992,825 |  |  | $ | 9,797,072 |
|  |  | 5,359,734 |  |  |  | 444,513 |  |  |  | 3,992,825 |  |  |  | 9,797,072 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 14: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration